: This biotechnology firm was a standout, posting a 426% return in 2017. Its growth was driven by positive clinical trial results for its cholesterol-reducing drug candidate.
: Another biotech leader, Nektar returned 387% following positive news regarding its immuno-oncology and painkiller treatments. high risk stocks to buy 2017
: A high-beta tech play that gained 109% due to a surge in demand and pricing for memory chips used in mobile devices and servers. Sector-Specific Risk Profiles : This biotechnology firm was a standout, posting